Investment & Growth Position Latigo as a high-potential, private-to-public growth-stage biotech with a recent $150M Series B and planned IPO. Sales opportunities exist in partnering discussions with CROs, contract manufacturing organizations, and potential licensees seeking later-stage non-opioid pain therapeutics or Nav1.8 inhibitor expertise.

Nav1.8 Focus Target pain management stakeholders with expertise in Nav1.8 inhibitors and non-opioid analgesics. Explore partnerships for co-development, externalized trial support, or out-licensing LTG-001 and related candidates to firms seeking to broaden non-opioid pain portfolios or accelerate go-to-market timelines.

Strategic Funding Signals Leverage Blue Owl Capital and other top-tier investors as credibility anchors in outreach to potential strategic partners, pharma licensees, or supply-chain collaborators. Highlight investor backing to de-risk collaborations and attract co-development funding.

Clinical Pathway & Timelines Engage clinical development and payer-focused entities by aligning on near-term milestones around LTG-001’s clinical progression. Present opportunities for early access programs, biomarker collaborations, and payer strategy input to shape future commercialization plans.

Market Positioning Differentiate Latigo from incumbents by emphasizing non-opioid, rapid-acting pain relief with lower addiction risk. Seek licensing or collaboration deals with mid-to-large biopharma seeking to expand non-addictive pain portfolios or to accelerate entry into acute pain indications similar to abdominoplasty contexts.